EP0591489A1 - Substituierte thiazolin-dioxetan-substrate, verfahren zur herstellung und verwendung - Google Patents

Substituierte thiazolin-dioxetan-substrate, verfahren zur herstellung und verwendung

Info

Publication number
EP0591489A1
EP0591489A1 EP93907842A EP93907842A EP0591489A1 EP 0591489 A1 EP0591489 A1 EP 0591489A1 EP 93907842 A EP93907842 A EP 93907842A EP 93907842 A EP93907842 A EP 93907842A EP 0591489 A1 EP0591489 A1 EP 0591489A1
Authority
EP
European Patent Office
Prior art keywords
compound
compounds
alkyl
group
straight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93907842A
Other languages
German (de)
English (en)
French (fr)
Inventor
Rupert Herrmann
Hans-Peter Josel
Christian Klein
Dieter Heindl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Boehringer Mannheim GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim GmbH filed Critical Boehringer Mannheim GmbH
Publication of EP0591489A1 publication Critical patent/EP0591489A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K11/00Luminescent, e.g. electroluminescent, chemiluminescent materials
    • C09K11/06Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
    • C09K11/07Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials having chemically interreactive components, e.g. reactive chemiluminescent compositions
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label

Definitions

  • the invention relates to thiazoline-dioxetane substrates, processes for the production and use in enzymatic analysis processes.
  • the object of the present invention was to provide a 1,2-dioxetane based on the activated intermediate of thiazolines and preferably luciferin, which is stable and only decomposes by reaction with an activating agent with the formation of chemiluminescence.
  • This object is achieved by a compound of the general formula III,
  • R- [and R2 are in each case identical or different and represent hydrogen or lower alkyl C 1 -C 4, straight-chain or branched
  • X is a cleavable group which can be cleaved off by an activating agent and at least one of the groups R4 or R5 represents a group stabilizing the dioxetane structure and at most one of the groups R4 or R5 represents hydrogen.
  • Acids, bases, salts, enzymes, inorganic or organic catalysts and Electron donors used are Acids, bases, salts, enzymes, inorganic or organic catalysts and Electron donors used.
  • the group -O-X can be located at any position on the phenyl ring.
  • R is a benzothiazole group
  • the group -O-X is preferably arranged in the 5-position.
  • R is a phenyl group
  • the group -O-X is preferably arranged in the 3-position. The same applies to the group -OR3, from which the group -O-X arises.
  • -O-X is preferably the hydroxy salt of an oxyacid, phosphate, aryl or alkyl carboxyl ester, alkyloxy or arylsilyloxy, sulfate, oxypyranoside.
  • composition of the aryl and alkyl radicals is not critical. Any person skilled in the art can select suitable radicals X without further ado. Solubility and cleavage of X by the activating agents must only be possible.
  • R1 and R2 are preferably hydrogen, methyl or ethyl groups. If, for example, phosphate is used as -O-X, the chemiluminescence reaction can be induced by adding alkaline phosphatase. When using the galactoside, the chemiluminescence reaction can be induced by ß-galactosidase. If a silyloxy radical is used as -O-X, the addition of fluoride can induce chemiluminescence.
  • Groups which protect the dioxetane group from reactions are suitable as groups R4 and / or R5 which stabilize the dioxetane structure. This stabilization is preferably carried out by sterically shielding this group.
  • R4 and R5 can be the same or different.
  • the adamantyl residue it is preferably bound in such a way that R4 and R5 represent parts of the ring structure and are therefore bridged (formula purple):
  • the compounds of general formula III are new. A synthetic method for these compounds is not yet known.
  • the invention accordingly also relates to a process for the preparation of the compounds of the formula III, which is characterized in that a compound of the formula IV or IVa.
  • R3 alkyl straight-chain or branched with 1 - 6 C- Represents atoms, preferably methyl or ethyl, with a compound of formula V.
  • R1 and R2 have the meanings given above, with the exclusion of water and air in the presence of an alkyllithium compound with aldehydes or ketones, decarboxylated the reaction product, dealkylated the alkoxy group, there the chemically labile group according to methods familiar to the skilled worker -OX introduces and photo-oxygenates to the dioxetane.
  • reaction of the compound of the formula IV (alkoxybenzothiazole-2-carboxylic acid nitrile) or IVa with the compound of the formula V (preferably penicillamine or cysteine) is preferably carried out in a polar solvent, such as water or water / alcohol mixtures, at room temperature with the exclusion of light.
  • a polar solvent such as water or water / alcohol mixtures
  • Suitable compounds as aldehydes and ketones are those which, as radical R4 and / or R5, stabilize the dioxetane structure of the compounds of the formula III. Such stabilization can be achieved by steric shielding of the dioxetane structure.
  • Suitable ketones and aldehydes are accordingly, for example, adamantanone, benzaldehydes, cyclohexanones, secondary and tertiary aliphatic aldehydes and ketones, such as. B. Di-t-butyl ketone.
  • R3 is preferably water-free in an aprotic organic solvent such as.
  • the alkyl lithium compound is preferably added as a solution in a hydrocarbon (pentane, hexane). Butyllithium is particularly preferably used. After the reaction has taken place, the compound obtained is precipitated from the reaction mixture, preferably by adding an aqueous salt solution at room temperature.
  • decarboxylation of the resulting ⁇ -hydroxycarboxylic acid to introduce a double bond is preferably carried out under dehydrating conditions, e.g. B. with diethyl azodicarboxylate and triphenylphosphine.
  • the dealkylation at the 6 'position is expediently carried out by adding a dealkylating agent such as trimethyl iodosilane. It is preferred to work anhydrous.
  • the thiazoline carboxylic acid can preferably be converted to a thiazolin-4-one via the intermediate stage of the amine and alcohol and then to a thiazolin-4-thione by reaction with sulfide.
  • This thiazolin-4-thione is reacted with a hydrazone of the aldehyde or ketone, preferably with adamantanone-2-hydrazone or benzaldehyde hydrazone, which can contain a removable group (adamantanontosyl hydrazone or benzaldehyde tosyl hydrazone) to give the compounds of the formula III according to the invention.
  • R4 and / or R5 represents a phenyl radical, an aliphatic radical or cycloalkyl radical, a substituted 2- Phenyl-5,5-dialkyl-thiazolin-4-one in a Grignard reaction to the 4-substituted derivative with subsequent introduction of a double bond at the 4-position of the thiazoline. Then, as described below, the dioxetane group is introduced.
  • the dioxetane group is expediently introduced by reacting the alkene derivative (double bond at the 2-position of the thiazoline), which is preferably dissolved in a polar organic solvent, such as methylene chloride or chloroform, at a temperature of -100-50 ° C and irradiation with visible light using a sensitizer (for example Rose Bengal, methylene blue, cf. Tetra ⁇ hedron Letters (1988) 3137 - 3140).
  • a sensitizer for example Rose Bengal, methylene blue, cf. Tetra ⁇ hedron Letters (1988) 3137 - 3140.
  • the supernatant contains the desired compound of formula III.
  • Another object of the invention is a method for determining an acid, base of a salt, enzyme, inorganic or organic catalyst and electron donor by reacting this compound with a compound of general formula III and measuring the light emitted as a measure of the content of the connection to be determined.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Materials Engineering (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
EP93907842A 1992-04-01 1993-03-29 Substituierte thiazolin-dioxetan-substrate, verfahren zur herstellung und verwendung Withdrawn EP0591489A1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE4210759A DE4210759A1 (de) 1992-04-01 1992-04-01 Substituierte Thiazolin-Dioxetan-Substrate, Verfahren zur Herstellung und Verwendung
DE4210759 1992-04-01
PCT/EP1993/000752 WO1993020083A1 (de) 1992-04-01 1993-03-29 Substituierte thiazolin-dioxetan-substrate, verfahren zur herstellung und verwendung

Publications (1)

Publication Number Publication Date
EP0591489A1 true EP0591489A1 (de) 1994-04-13

Family

ID=6455673

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93907842A Withdrawn EP0591489A1 (de) 1992-04-01 1993-03-29 Substituierte thiazolin-dioxetan-substrate, verfahren zur herstellung und verwendung

Country Status (5)

Country Link
US (3) US5455357A (ja)
EP (1) EP0591489A1 (ja)
JP (1) JPH06102669B2 (ja)
DE (1) DE4210759A1 (ja)
WO (1) WO1993020083A1 (ja)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4210759A1 (de) * 1992-04-01 1993-10-07 Boehringer Mannheim Gmbh Substituierte Thiazolin-Dioxetan-Substrate, Verfahren zur Herstellung und Verwendung
DE19538708A1 (de) * 1995-10-18 1997-04-24 Boehringer Mannheim Gmbh Heterocyclische Dioxetan-Substrate, Verfahren zur Herstellung und Verwendung
DE69720332T2 (de) * 1996-01-16 2003-12-04 Lumigen Inc Verbindungen, zusammensetzungen und methoden zur erzeugung von chemilumineszenz mit phosphatase-enzymen
US5876995A (en) 1996-02-06 1999-03-02 Bryan; Bruce Bioluminescent novelty items
US6247995B1 (en) 1996-02-06 2001-06-19 Bruce Bryan Bioluminescent novelty items
US6416960B1 (en) 1996-08-08 2002-07-09 Prolume, Ltd. Detection and visualization of neoplastic tissues and other tissues
CA2271717A1 (en) 1996-12-12 1998-06-18 Prolume, Ltd. Apparatus and method for detecting and identifying infectious agents
EP1925320A3 (en) 1998-03-27 2008-09-03 Prolume, Ltd. Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics
DE69938293T2 (de) 1998-03-27 2009-03-12 Bruce J. Beverly Hills Bryan Luciferase, gfp fluoreszenzproteine, kodierende nukleinsaüre und ihre verwendung in der diagnose
US7390670B2 (en) 2003-02-20 2008-06-24 Lumigen, Inc. Signalling compounds and methods for detecting hydrogen peroxide
SG11201903523YA (en) 2016-10-20 2019-05-30 Harvard College In vitro and cell based assays for measuring the activity of botulinum neurotoxins

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5068339A (en) * 1986-07-17 1991-11-26 Board Of Governors Of Wayne State University Enhanced chemiluminescence from 1,2-dioxetanes through energy transfer to tethered fluorescers
US5004565A (en) * 1986-07-17 1991-04-02 The Board Of Governors Of Wayne State University Method and compositions providing enhanced chemiluminescence from 1,2-dioxetanes
US5707559A (en) * 1986-07-17 1998-01-13 Tropix, Inc. Chemiluminescent 1,2-dioxetane compounds
US4983779A (en) * 1986-07-17 1991-01-08 The Board Of Governors Of Wayne State University Process for the preparation of vinyl ethers
US4959182A (en) * 1986-07-17 1990-09-25 Board Of Governors Of Wayne State University Method and compositions providing enhanced chemiluminescence from 1,2-dioxetanes
US5013827A (en) * 1986-07-17 1991-05-07 Board Of Governors Of Wayne State University Enhanced chemiluminescence from 1,2-dioxetanes through energy transfer to tethered fluorescers
US4857652A (en) * 1986-07-17 1989-08-15 Board Of Governors Of Wayne State University Chemiluminescent 1,2-dioxetane compounds
US4962192A (en) * 1986-07-17 1990-10-09 Board Of Governors Of Wayne State University Chemiluminescent 1,2-dioxetane compounds
US5089630A (en) * 1987-12-31 1992-02-18 Bronstein Irena Y Dioxetanes for use in assays
DE68917387T2 (de) * 1987-12-31 1994-12-22 Tropix Inc Dioxetane zur verwendung bei immuntests.
DE4210759A1 (de) * 1992-04-01 1993-10-07 Boehringer Mannheim Gmbh Substituierte Thiazolin-Dioxetan-Substrate, Verfahren zur Herstellung und Verwendung

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9320083A1 *

Also Published As

Publication number Publication date
US5994552A (en) 1999-11-30
WO1993020083A1 (de) 1993-10-14
US5455357A (en) 1995-10-03
JPH06503844A (ja) 1994-04-28
DE4210759A1 (de) 1993-10-07
US5712106A (en) 1998-01-27
JPH06102669B2 (ja) 1994-12-14

Similar Documents

Publication Publication Date Title
EP0040177A1 (de) Verfahren zur Herstellung von Alkenylbenzol- oder -naphthalincarbonsäurederivaten
EP0591489A1 (de) Substituierte thiazolin-dioxetan-substrate, verfahren zur herstellung und verwendung
DE69909611T2 (de) Reagenz zum nachweis von singulett-sauerstoff
EP0167973B1 (de) Redox-Indikatoren
EP0007019A1 (de) Neue 5-Phenylpyrazol-Derivate und ihre Salze; Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
EP0218541A2 (de) 3-Vinyl- und 3-Ethinyl-beta-carbolinderivate, ihre Herstellung und ihre Verwendung als Arzneimittel
DE60125958T2 (de) Reagenzien zur bestimmung von atomaren sauerstoff
DE69910642T2 (de) 1,2-Dioxetanderivate
EP0273270A1 (de) Verfahren zur Herstellung von (+)-Biotin
DE2003461A1 (de) Verfahren zur Herstellung von 2-Alkylpyridaziniumverbindungen
EP0863906B1 (de) Heterocyclische dioxetan-substrate, verfahren zur herstellung und verwendung
DE1795147A1 (de) Verfahren zur Herstellung von Sauerstoffderivaten des Indols
DE2814747C2 (de) Verfahren zur Herstellung von Androsta-4,9(11)-dien-3,17-dionen durch saure Dehydratisierung von 9α-Hydroxyandrostendionen
DE60003598T2 (de) Mit einem Pyranring kondensierte 1,2-Dioxetan-Derivate und ihre Verwendung
EP0513700B1 (de) Verfahren zur Herstellung von Imidazothiazolon-Derivaten
DE2652892A1 (de) Substituierte aminobenzaldehydverbindungen
Shalaby et al. Reactivity of the Exocyclic Double Bond in 5‐arylidene derivatives of barbituric and thiobarbituric acids
DE2644789A1 (de) Alkylen-di-phenylalk(en)ylcarbonsaeuren und ihre herstellung und verwendung
DE1620023A1 (de) Verfahren zum Herstellen von Indolyl-essigsaeure-Verbindungen
AT404724B (de) Neue zwischenverbindung und verfahren zur herstellung von antihypercholesterinämisch wirkenden tetrazolverbindungen
DE1643226A1 (de) Photochrome Verbindungen und ihre Herstellung
DE2820862A1 (de) Chromanderivate
EP0036159A1 (de) 4-(2,5-Dihydroxyphen-1-yl)-crotonsäure und deren Derivate sowie Verfahren zur Herstellung dieser Verbindungen
EP0019132A1 (de) Verfahren zur Herstellung von alpha-Halogencyclobutanonen
JPH05117241A (ja) 4−ヒドロペルオキシ−2−(n,n−ジ置換アミノフエニル)−4,5−ジフエニル−4h−イソイミダゾール

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19931027

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

17Q First examination report despatched

Effective date: 19970807

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ROCHE DIAGNOSTICS GMBH

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20001130